这是一种首创的MAPK13抑制剂,可以纠正干细胞重编程和创伤后疾病
Yong Zhang1, Kangyun Wu1, Dailing Mao1
1Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
bioRxiv : the preprint server for biology
|September 4, 2024
概括
研究人员开发了NuP-4,一种新的MAPK13抑制剂,用于治疗肺损伤. 这种化合物有效地逆转疾病修饰和炎症,为后病毒性疾病提供了潜在的治疗方法.
科学领域:
- 细胞和分子生物学 细胞和分子生物学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 基激活蛋白激酶13 (MAPK13),也称为p38δ-MAPK,在表皮屏障损伤后的结构重塑中起着关键作用.
- 由于缺乏选择性,安全和有效的抑制剂,目前对涉及MAPK13失调的疾病的治疗选择有限.
研究的目的:
- 确定和描述一种新的,选择性抑制MAPK13.
- 在肺损伤和疾病的临床前模型中评估这种抑制剂的治疗潜力.
主要方法:
- 使用基于结构的药物设计和选漏斗,结合细胞安全性和分子特异性评估.
- 鉴定出来的抑制剂 (NuP-4) 的疗效在小鼠模型和病毒后肺病的器官菌种中进行了评估.
- 分析了对基本上皮质干细胞重编程,结构重塑,炎症和细胞因子刺激反应的影响.
主要成果:
- 首个同类MAPK13抑制剂NuP-4的成功鉴定.
- NuP-4在小鼠模型中表现出相当于Mapk13基因淘汰的疗效,降低调节干细胞重编程,结构重塑和病理生理学.
- 治疗效益,包括疾病修饰和逆转炎症和重塑,在治疗停止后仍然存在. NuP-4还控制了细胞因子刺激的人类基底细胞有机体的生长和分化.
结论:
- NuP-4代表了一个有希望的治疗候选人,用于管理长期干细胞重编程和病毒损伤后的相关病理.
- 这种新型抑制剂为针对MAPK13介导疾病的实验和潜在临床应用提供了宝贵的工具.
- 这些发现表明,对于MAPK13诱导和激活的特征有潜在的治疗策略.
关键词:
喘 喘 是一种慢性阻塞性肺病 (COPD) 是一种慢性阻塞性肺病.皮质干细胞的表皮干细胞.炎症性记忆 炎症性记忆是一种记忆.长期的Covid 疾病基激活蛋白激酶 (MAPK) 是一种激活蛋白激酶.在p38-MAPKK中使用.呼吸道病毒感染 呼吸道病毒感染更多相关视频
07:18A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening
Published on: May 12, 2017
6.4K
08:25Reprogramming Human Somatic Cells into Induced Pluripotent Stem Cells iPSCs Using Retroviral Vector with GFP
Published on: April 3, 2012
20.5K
相关概念视频
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
01:29Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
01:06Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:24Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K